VC-backed JenaValve appoints new CEO
Munich, Germany and Irvine, California-based JenaValve Technology, a provider of transcatheter aortic valve implantation systems that treat aortic valve disease, has named Dr. Victoria E. Carr-Brendel as CEO. The appointment is effective immediately. Previously, Dr. Carr-Bendel served as general manager of Boston Scientific’s Bayer Interventional business. Its backers include Atlas Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds, Biovest and Valiance Advisors.
2 June 2015•3 mins read
